News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Elyse Hall Panjic, PharmD, BCOP

Articles by Elyse Hall Panjic, PharmD, BCOP

100 Non-Pharmacological Interventions for Managing Abemaciclib-Associated Adverse Events in Patients With Early/Advanced HR+/HER2– Breast Cancer: A US-Based Health Care Provider Survey

ByAlexandra Vitko,Pamela K Ginex,Kelli Thoele,Qinli Lily Ma,Astra Liepa,Wambui Gathirua-Mwangi,Elyse Hall Panjic, PharmD, BCOP,Engels Chou,Jodi L Taraba,Hilary Ellis,Charlotte Clewes,Joanna de Courcy,Hope S. Rugo, MD

April 15th 2025

How to Decide Which DLBCL Patients Should Receive CNS Prophylaxis

ByKevin H. Hall, PharmD, BCOP,Elyse Hall Panjic, PharmD, BCOP,Kelly Valla, PharmD, BCOP,Christopher R. Flowers, MD, MS,Jonathon B. Cohen, MD, MS

June 15th 2018

Here we review current prognostic models, risk factors, and prophylaxis methods to provide a practical approach to preventing CNS relapse in patients with DLBCL.

Latest Updated Articles

How to Decide Which DLBCL Patients Should Receive CNS Prophylaxis
June 15th 2018

Trending on CancerNetwork

FDA Approves Gedatolisib for HR+, HER2– PIK3CA Wild-Type Advanced Breast Cancer

Agenus Discontinues Phase 3 BATTMAN Trial in Metastatic MSS Colorectal Cancer

FDA Traditionally Approves Selpercatinib in RET+ Solid Tumors

Subcutaneous Isatuximab Approval Expands Options in Multiple Myeloma

Radiotherapy Regimen Shows Responses in Anti–PD-1–Refractory NSCLC